Search Results
Sep 04, 2025, 16:05 ET Ramaco Retains Hatch to Lead Pre-Feasibility Study for Brook Mine REE/CM Project
Brook Mine rare earth elements and critical minerals (REE/CM) project. Hatch will spearhead the development of the project's Pre-Feasibility Study (PFS), including test-work support, pilot plant design, and process flowsheet optimization. This milestone follows a rigorous evaluation of proposals
More news about: Ramaco Resources, Inc.
Sep 03, 2025, 08:30 ET ARIS MINING ANNOUNCES POSITIVE PREFEASIBILITY STUDY RESULTS FOR THE SOTO NORTE GOLD PROJECT IN COLOMBIA
disclosures, announces positive results from the recently completed prefeasibility study (PFS) of its 51%-owned Soto Norte Gold Project (Soto Norte or the Project) in Santander, Colombia. The PFS confirms Soto Norte as a high-quality project with robust economics, low operating
More news about: Aris Mining Corporation
Sep 02, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA®; future safety and efficacy
More news about: ADC Therapeutics SA
Sep 02, 2025, 12:28 ET New AICPA Survey Finds 74% of Americans Who Have Personal Student Loans are Worried About Their Ability to Pay Those Loans Back
loans. "Student loans are more than a monthly payment – they're a long-term financial commitment," says Pamela Ladd, CPA/PFS, senior manager of Personal Financial Planning for the American Institute of CPAs. "The fact that three-quarters of borrowers are worried about repaying
More news about: AICPA
Aug 27, 2025, 07:15 ET ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025
LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA®; future safety and efficacy results
More news about: ADC Therapeutics SA
Aug 26, 2025, 12:52 ET Akeso's 2025 Interim Results: Commercial Sales Reach New All-Time Highs
survival (PFS), but also highlight its ability to deliver significant OS improvement, a key endpoint in global oncology drug development. During the reporting period, an interim analysis of the first global multicenter Phase III trial (HARMONi) also demonstrated strongly positive PFS outcomes.
More news about: Akeso, Inc.
Aug 25, 2025, 03:00 ET Antengene Announces 2025 Interim Results with Encouraging Clinical Data and Progress in TCE Platform
moderate-to-high expressors (IHC 2+ >20%), the 2.4 mg/kg cohort achieved a 40% ORR (12/30, including 1 CR), a 90% DCR, 6.97 months of mPFS, with 6-month PFS at 51.1%, 9-month OS at 82.7%, and 12-month OS at 66.2%; the 1.8 mg/kg cohort achieved 40% ORR (10/25, including 1 CR) and 84% DCR. In low/ultra-low
More news about: Antengene Corporation Limited
Aug 24, 2025, 20:00 ET Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
comparison to traditional chemotherapy, IBI363 appears to offer potential advantages in both objective response rate (ORR) and progression-free survival (PFS), providing new hope for patients diagnosed with lung cancer." Professor Shun Lu from the Oncology Department
More news about: Innovent Biologics
Aug 22, 2025, 07:00 ET Grounded Lithium Reports Second Quarter 2025 Financial and Operating Results, Provides Corporate Update and Grant of Incentive Stock Options
partner, Denison Mines Ltd ("Denison"), as it progresses to develop and finalize a pre-feasibility study ("PFS") anticipated to be completed towards the end of 2025 or early 2026. The PFS will provide clear conclusions on the economics, viability and development path for the Company's flagship
More news about: Grounded Lithium Corp.
Aug 22, 2025, 06:11 ET Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform
including 1 complete response (CR), with a disease control rate (DCR) of 90% (27/30), a median progression-free survival (mPFS) of 6.97 months, a 6-month PFS rate of 51.1%, a 9-month overall survival (OS) rate of 82.7%, and a 12-month OS rate of 66.2%. The 1.8 mg/kg dose cohort achieved an ORR of 40%
More news about: Antengene Corporation Limited
Aug 19, 2025, 06:39 ET Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
Complete Response (CR)Disease Control Rate (DCR): 90% (27/30)Median Progression-free Survival (mPFS): 6.97 months6-month PFS Rate: 51.1%9-month Overall Survival (OS) Rate: 82.7%12-month OS Rate: 66.2%1.8 mg/kg CohortORR: 40% (10/25),
More news about: Antengene Corporation Limited
Aug 19, 2025, 00:42 ET Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
Complete Response (CR)Disease Control Rate (DCR): 90% (27/30)Median Progression-free Survival (mPFS): 6.97 months6-month PFS Rate: 51.1%9-month Overall Survival (OS) Rate: 82.7%12-month OS Rate: 66.2% 1.8 mg/kg CohortORR:
More news about: Antengene Corporation Limited
Aug 18, 2025, 08:30 ET Foresight Diagnostics Announces Publication of Landmark Study Demonstrating Prognostic Value of Ultrasensitive ctDNA-MRD Detection in Large B-Cell Lymphoma
a 2-year progression-free survival (PFS) of 96% compared to 67% for patients with detectable MRD (hazard ratio 6.9; p=0.0025).ctDNA-MRD assessment was most prognostic at end of therapy: 78% of patients were MRD-negative and had a 2-year PFS of 97%, compared to just 29% among
More news about: Foresight Diagnostics, Inc.
Aug 18, 2025, 06:21 ET KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
therapy and platinum-based chemotherapy. Sac-TMT monotherapy demonstrated a statistically significant and clinically meaningful improvement in ORR, PFS and OS compared with docetaxel. In addition, a Phase 3 registrational study of sac-TMT combined with osimertinib as first-line treatment of locally advanced
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Aug 14, 2025, 20:15 ET CARsgen Therapeutics Announces 2025 Interim Results
orally presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Satri-cel demonstrated significant progression-free survival (PFS) improvement and a clinically meaningful overall survival (OS) benefit with a manageable safety profile, compared to standard therapy. Multiple
More news about: CARsgen Therapeutics
Aug 14, 2025, 07:00 ET Leap Therapeutics Reports Second Quarter 2025 Financial Results
blinded independent central review, and progression-free survival (PFS) in patients with high levels of DKK1, no prior exposure to anti-VEGF therapy, or liver metastasis, along with a positive trend on ORR and PFS in the full intent-to-treat population. The final data from the
More news about: Leap Therapeutics, Inc.
Aug 14, 2025, 07:00 ET BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
standard chemotherapy (gemcitabine and nab-paclitaxel). A prespecified interim analysis is planned when 40% of progression-free survival (PFS) events are observed.An abstract featuring updated data from the pilot phase of the ongoing CheMo4METPANC clinical trial was presented at the
More news about: BioLineRx Ltd.
Aug 13, 2025, 14:08 ET HopeAI Showcases AI-Powered Synthetic Data to Speed Up Cancer Drug Trials at ASCO 2025
datasets.Demonstrated Impact in Multiple Myeloma: The analysis confirmed a moderate surrogacy relationship between MRD negativity and progression-free survival (PFS) across recent myeloma trials, supporting its utility as a regulatory endpoint.Speed and Efficiency: Compared to traditional pooled analyses
More news about: HopeAI, Inc.
Aug 12, 2025, 07:30 ET ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
2027.LOTIS-5 remains on track to reach prespecified progression-free survival (PFS) events by the end of 2025. After the prespecified number of PFS events is reached and data are available, the Company expects to provide topline data on the Phase 3 confirmatory
More news about: ADC Therapeutics SA
Aug 12, 2025, 04:41 ET 克服標靶藥副作用挑戰，平衡肺癌治療與生活品質
三代 ALK 標靶藥 PFS 表現雖領先，二代藥物安全性仍具優勢 不少 ALK 陽性的 NSCLC 病人在確診時已屆晚期，加上呈現 ALK 基因突變的個案比其他肺癌更容易發生腦轉移，令病人的存活率及生活品質蒙上更大陰影。所幸過去十多年來標靶藥物發展迅速，比起傳統化療不但能進一步延長病人的無惡化存活期（PFS），也能穿透血腦屏障，從而預防腦轉移發生或延緩現有腦轉移惡化。根據在美國臨床腫瘤學會（ASCO）2024 年會中發表的 3 期臨床試驗資料，第三代的口服標靶藥更呈現出優異的 PFS 數據，5 年無惡化存活率可高達 60%。
More news about: 基因線上
Aug 12, 2025, 03:52 ET 慎選用藥提升標靶治療續航力，為晚期肺癌病人帶來生命曙光
年左右的穩定控制，對晚期肺癌病人來講，是相當珍貴的成果。」當然，他也坦言有個別服用二代標靶藥的病人撐不到三年就惡化，所幸現有框架允許此類個案馬上申請改用第三代藥物，這樣的安排既有助提升治療彈性，也有望延長治療週期，讓癌友有機會期待日後更多新藥出現。 蔡醫師進一步指出：「第三代標靶藥在延長 PFS 方面的表現確實令人驚艷，只是多數病人本身都不太會在確診頭三年內病情惡化。如果在這個階段就選用副作用較明顯的藥物，病人或許得到了延長 PFS 的好處，卻可能要冒上犧牲三年生活品質的風險。」所以歸根究底，在蔡醫師心目中，最重要的還是要精準判斷不同個案的狀況跟需求（例如基因突變情況、對治療的期待、是否有共病症等等），然後選擇最適切的藥物來治療——畢竟「世界上沒有後悔的藥」。
More news about: 基因線上
Aug 11, 2025, 07:00 ET U.S. GoldMining Advances Planning With State of Alaska Officials for Critical Road Infrastructure to the Whistler Gold-Copper Project, Alaska
and the long-term development of Whistler." About the Proposed West Susitna Access Project The WSAP comprises two elements: ADOT&PF's project to build 22-miles of new public road extending west from the existing road network in Southcentral Alaska, and a further 78.5-miles of public
More news about: U.S. GoldMining Inc.
Aug 10, 2025, 22:52 ET Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy
cancer. In previous studies focused on extensive-stage SCLC (ES-SCLC), ivonescimab has demonstrated its ability to prolong progression-free survival (PFS), combining the synergistic benefits of PD-1/L1 inhibitors and anti-angiogenic agents. Ivonescimab is a cornerstone in Akeso's "IO 2.0" strategy, and
More news about: Akeso, Inc.
Aug 07, 2025, 23:38 ET Intas Pharmaceuticals und Accord BioPharma werden mit der Übernahme von UDENYCA® zu einem der weltweit größten Anbieter von Pegfilgrastim
verbunden ist, zu senken. UDENYCA bietet drei patientenfreundliche Verabreichungsoptionen – Autoinjektor (AI), On-Body-Injektor (OBI) und Fertigspritze (PFS) – und damit Flexibilität für die Behandlung zu Hause, unterwegs oder in klinischen Einrichtungen. Seit der Markteinführung wurden über 300 000 Patienten
More news about: Accord Healthcare
Aug 07, 2025, 17:00 ET ARIS MINING REPORTS Q2 2025 RESULTS
A new Pre-Feasibility Study (PFS) is underway, with completion expected in Q3 2025. The PFS incorporates a smaller-scale development plan and includes processing options designed to support local small-scale miners.Upon completion of the PFS, Aris Mining intends to finalize and submit
More news about: Aris Mining Corporation